Defence Therapeutics Inc. (OTCMKTS:DTCFF) Short Interest Update

Defence Therapeutics Inc. (OTCMKTS:DTCFF) was the recipient of a significant decrease in short interest in June. As of June 15th, there was short interest totalling 1,600 shares, a decrease of 5.9% from the May 31st total of 1,700 shares. Based on an average trading volume of 1,300 shares, the short-interest ratio is currently 1.2 days.

Defence Therapeutics Price Performance

DTCFF stock traded up $0.08 during mid-day trading on Tuesday, hitting $0.65. 1,000 shares of the company were exchanged, compared to its average volume of 796. The firm has a fifty day simple moving average of $0.85 and a 200 day simple moving average of $1.22. Defence Therapeutics has a twelve month low of $0.57 and a twelve month high of $3.19.

About Defence Therapeutics

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.